Sunday, 11 October 2026 Updated 56 min ago
The News Engine
Breaking
Health United States

Bowel cancer “melted away” after immunotherapy, then stayed away

A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer.

ScienceDaily reports that a short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer.

In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy.

This health story centres on the United States.

Why it matters

Health stories are worth following because they can shape treatment options, guidance and how services are delivered. Readers should rely on medical professionals for personal advice.

Key details

Location
United States · Americas
Reported by
ScienceDaily
First reported
Key names
the NEOPRISM-CRC
Section
Health

Sources

This is an independent summary. Read the full, original reporting from the publisher:

Read the full story at ScienceDaily

Spotted an error? Request a correction · How this summary was produced

Related Stories